Vaccines 2023, 11(1), 130; https://doi.org/10.3390/vaccines11010130 - 5 Jan 2023
Best Paper Award
Dear Colleagues,
We are pleased to announce the winners of the Vaccines 2021 Best Paper Award. All papers published in Vaccines from 1 January 2021 to 31 December 2021 were considered for the award. After a thorough evaluation of the originality and significance of the papers, citations, and downloads, four winners were selected.
Two Reviews
(CHF 400 and a chance to publish a free paper in 2023 after peer review):
Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic
By Masaki Machida, Itaru Nakamura, Takako Kojima, Reiko Saito, Tomoki Nakaya, Tomoya Hanibuchi, Tomoko Takamiya, Yuko Odagiri, Noritoshi Fukushima, Hiroyuki Kikuchi, Shiho Amagasa, Hidehiro Watanabe and Shigeru Inoue
Vaccines 2021, 9(3), 210; https://doi.org/10.3390/vaccines9030210
Willingness to Receive COVID-19 Vaccination in Japan
By Takeshi Yoda and Hironobu Katsuyama
Vaccines 2021, 9(1), 48; https://doi.org/10.3390/vaccines9010048
Two Articles
(CHF 500 and a chance to publish a free paper in 2023 after peer review):
Nanomaterial Delivery Systems for mRNA Vaccines
By Michael D. Buschmann, Manuel J. Carrasco, Suman Alishetty, Mikell Paige, Mohamad Gabriel Alameh and Drew Weissman
Vaccines 2021, 9(1), 65; https://doi.org/10.3390/vaccines9010065
Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines
By Thai Thanh Hoang Thi, Estelle J. A. Suys, Jung Seok Lee, Dai Hai Nguyen, Ki Dong Park and Nghia P. Truong
Vaccines 2021, 9(4), 359; https://doi.org/10.3390/vaccines9040359
Please join us in congratulating the winners of the Vaccines 2021 Best Paper Award. We would also like to take this opportunity to thank all of our authors for your continued support of Vaccines.
Kind regards,
Vaccines Editorial Office
Vaccines 2021 Best Paper Award
Eligibility and Requirements
– All papers published in Vaccines will be eligible (Both regular and Special Issue submissions).
Past Winners
Year:
Winner
An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
Factors Influencing Antibody Response to SARS-CoV-2 Vaccination
Vaccines 2023, 11(2), 451; https://doi.org/10.3390/vaccines11020451 - 15 Feb 2023
The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR): An Update and Future Perspectives
Vaccines 2023, 11(2), 333; https://doi.org/10.3390/vaccines11020333 - 1 Feb 2023
Award Committee
Dr. Ralph Tripp
Chairman
Univ Georgia
Prof. Christian Napoli
Department of Medical surgical sciences and translational medicine - Sapienza University of Rome
Dr. Zixin Wang
JC School of Public Health and Primary Care, the Chinese University of Hong Kong
Prof. Michael Bukrinsky
The George Washington University
Dr. Mariusz Skwarczynski
University of Queensland
Winner
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Vaccines 2022, 10(5), 819; https://doi.org/10.3390/vaccines10050819 - 22 May 2022
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
Vaccines 2022, 10(2), 227; https://doi.org/10.3390/vaccines10020227 - 2 Feb 2022
Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women
Vaccines 2022, 10(1), 101; https://doi.org/10.3390/vaccines10010101 - 10 Jan 2022
Award Committee
Dr. Ralph Tripp
Chairman
Univ Georgia
Prof. Michael Bukrinsky
The George Washington University
Prof. Christian Napoli
Department of Medical surgical sciences and translational medicine - Sapienza University of Rome
Prof. Sara Louise Cosby
Queen's University Belfast
Dr. Yashdeep Phanse
University of Wisconsin-Madison
Winner
Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic
Vaccines 2021, 9(3), 210; https://doi.org/10.3390/vaccines9030210 - 3 Mar 2021
Willingness to Receive COVID-19 Vaccination in Japan
Vaccines 2021, 9(1), 48; https://doi.org/10.3390/vaccines9010048 - 14 Jan 2021
Nanomaterial Delivery Systems for mRNA Vaccines
Vaccines 2021, 9(1), 65; https://doi.org/10.3390/vaccines9010065 - 19 Jan 2021
Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines
Vaccines 2021, 9(4), 359; https://doi.org/10.3390/vaccines9040359 - 8 Apr 2021
